Table 1 Included study and patient characteristics
Author | Year | Country | Study design | Patients | Sex (M/F) | Age (years) | Diagnosis | Stem cells | Administration routes | Follow-up (mth) |
|---|---|---|---|---|---|---|---|---|---|---|
Nittala [38] | 2021 | USA | Multicentre PCT | 15 | – | – | Dry AMD | HuCNS-SCs | Subretinal | 12 |
Kashani [34] | 2021 | USA | Non-randomised PCT | 16 | 7/9 | 69–85 | Dry AMD | hESC-RPE | Subretinal | 12 |
Oner [23] | 2018 | Turkey | PCT | 8 | 5/3 | 19–75 | Dry AMD or SMD | ADSCs | Suprachoroidal | 6 |
Limoli [36] | 2018 | Italy | Randomised PCT | 25 | 14/11 | 62–84 | Dry AMD | ADSCs | Suprachoroidal | 6 |
Cotrim [33] | 2017 | Brazil | PCT | 10 | – | – | Dry AMD | BM with CD34 + SCs | Intravitreal | 12 |
Limoli [35] | 2016 | Italy | Non-randomised PCT | 25 | 9/16 | 64–84 | Dry AMD | ADSCs | Suprachoroidal | 6 |
Song [41] | 2015 | Republic of Korea | PCT | 4 | – | – | Dry AMD or SMD | hESC-RPE | Subretinal | 12 |
Schwartz [40] | 2015 | USA | Non-randomised PCT | 18 | – | 20–88 | Dry AMD or SMD | hESC-RPE | Subretinal | 12 |
Park [39] | 2014 | USA | PCT | 6 | 4/2 | 23–85 | Dry AMD or SMD or RP or CRAO | BM with CD34 + SCs | Intravitreal | 6 |
Limoli [37] | 2014 | Italy | PCT | 12 | 6/6 | 62–80 | Dry AMD | ADSCs | Suprachoroidal | 1 |